Prospective evaluation of clinical parameters of AAT patients with iv. Prolastin therapy in a homecare setting;Prospektive Untersuchung klinischer Verlaufsparameter von Patienten mit Alpha-1-Antitrypsinmangelsyndrom unter i. v. Prolastin-Heimtherapie

Pneumologie

Volumn 67, Issue 10, 2013, Pages 545-550

  Wilke, A ^a   Grohe C ^a  

^a Klinik fur Pneumologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DISEASE COURSE; FORCED EXPIRATORY VOLUME; HOME CARE; HUMAN; INFUSION; LUNG FUNCTION; LUNG FUNCTION TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPIROMETRY; VITAL CAPACITY;

ADULT; AGED; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; FEMALE; HOME NURSING; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SERINE PROTEINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84885633306     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0033-1344554     Document Type: Article

References (25)

1. American Thoracic Society European Respiratory Society Standards in Diagnostik und Therapie bei Patienten mit Alpha-1-Antitrypsin-Mangel. Pneumologie: 2005; 59 36 68
2. 1-antitrypsin defiency. Ther Adv Respir Dis: 2010; 4 279 287
3. 1-antitrypsin defiency in COPD patients. Eur Respir J: 2005; 26 616 622 (Pubitemid 41448658)
4. 1-Antitrypsin defiency and lung disease: risk modification by occupational and environmental inhalants. Eur Respir J: 2005; 26 909 917 (Pubitemid 41632051)
5. 1- antitrypsin defiency. Am J Respir Crit Care Med: 2012; 185 246 259
6. Vogelmeier C., Hamacher J., Steveling H. et al. Alpha-1-Antitrypsin- Mangel: Update. Pneumologie: 2009; 63 718 725
7. Vijayasaratha K., Stockley R. A. Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1-antitrypsin deficient COPD. Intern J of COPD: 2012; 7 789 796
8. Thornton J., Elliott R. A. et al. Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: comparing hospital and home care. J Cyst Fibros: 2005; 4 239 247 (Pubitemid 43013031)
9. Schmid S., Noeske S. et al. Effekte der Augmentationstherapie auf pulmonale sowie systemische Entzündungsmarker bei Patienten mit heriditärem alpha1-Antitrypsin Mangel. Pneumologie: 2011; 65 P272
10. Bhole M. V., Burton J., Chapel H. M. Self-infusion programmes for immunglobulin replacement at home: feasibility, safety and efficacy. Immunol Allergy Clin N Am: 2008; 28 821 832
11. Bundesministerium für Gesundheit Bundesanzeiger Nr. 46 (S. 1128). 21 03 2012
12. Cats E. A., de Vanr Pol W. L. et al. Home-based IVIg treatment is convenient and time- saving in patients with multifocal motor neuropathy. J Peripher Nerv Syst: 2011; 16 147 149
13. Depledge J., Gracie F. Developing a strategic approach for IV therapy in the community. Brit J of Community Nursing: 2006; 11 462 468
14. Esmond G., Butler M., MyCormack A. M. Comparison of hospital and home intravenous antibiotic therapy in adults with cystic fibrosis. J Clin Nursing: 2006; 15 52 60 (Pubitemid 43455092)
15. Matthews P. C., Conlon C. P. et al. Outpatient parental antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohoert over 13 years. J Antimicrob Chemoth: 2007; 60 356 362 (Pubitemid 47243886)
16. Mighten J. Home intravenous therapy training for carers of children and young people. Brit J of Nursing: 2007; 16 272 276
17. Milligan A., Hughes D. et al. Intravenous enzyme replacement therapy: better in home or hospital? Brit J of Nursing: 2006; 15 330 333
18. Petrini P., Rylander C. Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto utilizing a com-puter-aided diary: a Nordic multicentre study. Haemophilia: 2009; 15 175 183
19. Schroth S., Koczulla R. et al. Alpha-1-Antitrypsin-Mangel: Diagnose und Therapie der pulmonalen Erkrankung. Pneumologie: 2009; 63 335 345
20. 1-antitrypsin defiency. Thorax: 2003; 58 1020 1026
21. 1-antitrypsin defiency and factors associated with decline. Am J Respir Crit Care Med: 2001; 164 1805 1809 (Pubitemid 33152311)
22. 1-antitrypsin and tobacco smoke exposure. Eur Respir J: 2002; 19 1099 1106
23. 1-antitrypsin defiency. Am J Respir Crit Care Med: 2003; 167 1387 1392 (Pubitemid 36609724)
24. 1- antitrypsin defiency. Chest: 2011; 140 198 204
25. 1-protease inhibitor. Chest: 2001; 119 737 744 (Pubitemid 32197642)